

gloveon Paloma

Nitrile Exam Gloves Powder Free, Standard Cuff



To don **Paloma** is like putting on a second skin. Its absolute tactility commends it to delicate procedures and jobs plus an assured tensile strength and resistance to chemical expected of a nitrile glove. You owe it to yourself to try this exceptional nitrile glove from **GloveOn**.

GloveOn Paloma		
Length (mm)	≥ 230	
Thickness Measurements (mm)		
Palm (centre of Palm)	0.07 ± 0.02	
Finger (13mm ± 3mm from tip)	0.09 ± 0.02	
Physical Properties	Before Ageing	After Ageing
Tensile Strength (MPa)	≥ 18	≥ 16
Elongation (%)	≥ 500	≥ 400
Inspection Levels & AQL	Inspection Level	AQL
Watertightness	G1	1.5
Physical Dimensions	S2	4.0
Physical Properties	S2	4.0
Visual Inspection (Major)	S4	2.5
Visual Inspection (Minor)	S4	4.0
Particulate Residue	N = 5	≤ 2mg/glove

Chemotherapy Drugs and Concentration (Tested for Resistance to Permeation by Chemotherapy Drugs as per ASTM D6978-05)	Minimum Breakthrough Detection Time (minutes)
Carmustine (BCNU), 3.3mg/ml (3,300 ppm)	16.2 minutes
Cisplatin, 1.0mg/ml (1,000 ppm)	>240 minutes
Cyclophosphamide (Cytosan), 20.0mg/ml (20,000 ppm)	>240 minutes
Dacarbazine (DTIC), 10.0mg/ml (10,000 ppm)	>240 minutes
Doxorubicin Hydrochloride, 2.0mg/ml (2,000 ppm)	>240 minutes
Etoposide (Toposar), 20.00mg/ml (20,000 ppm)	>240 minutes
Fluorouracil, 50.0mg/ml (50,000 ppm)	>240 minutes
Methotrexate, 25.0mg/ml (25,000 ppm)	>240 minutes
Mitomycin C, 0.5mg/ml (500 ppm)	>240 minutes
Paclitaxel (Taxol), 6.0mg/ml (6,000 ppm)	>240 minutes
Thiotepa, 10.0mg/ml (10,000 ppm)	28.4 minutes
Vincristine Sulfate, 1.0mg/ml (1,000 ppm)	>240 minutes

WARNING: Carmustine and Thiotepa, at the tested concentration, degraded Paloma nitrile glove at 16.2 minutes and 28.4 minutes, respectively. The safe use of gloves in chemotherapy treatment is solely the decision of clinicians authorised to make such a decision.

FEATURES

- Fingertip textured
- Powder free
- Not made with natural rubber latex
- Chemo drugs tested
- Lab chemical tested
- Ambidextrous
- Violet blue colour

PACKAGING

100 gloves per box
10 boxes per carton

REGULATORY COMPLIANCE

FDA 510(k), MDD 93/42/EEC,
REACH, ROHS Directive 2002/95/EC,
EC 10/2011, EC 1935/2004

STANDARDS

ASTM D6319, ASTM D412, ASTM D573,
ASTM D5151, ASTM D6124,
EN455 part 1, 2, 3 & 4, EN 1186,
EN 13130, CEN/TS 14234

MANUFACTURING ACCREDITATIONS

ISO 9001
ISO 13485
EN ISO 13485



Certificate of CE-Registration

This is to certify that, in accordance with the Medical Device Directive 93/42/EEC, Medical Device Safety Service GmbH (MDSS) agrees to perform all duties and responsibilities as the Authorized Representative for:

**Hartalega NGC Sdn. Bhd.
No. 1, Persiaran Tanjung
Kawasan Perindustrian Tanjung
43900 Sepang, Selangor
MALAYSIA**


as stipulated and demanded by the aforementioned Directive. The German Competent Authority has allocated the medical devices of the Manufacturer registration numbers as foreseen in:

Annex A dated January 18, 2019

The Manufacturer has provided MDSS with the appropriate Declaration(s) of Conformity confirming that the medical devices fulfill the applicable requirements of Directive 93/42/EEC. In compliance with German law, a safety officer has been appointed for Germany.

2019-01-18


Ludger Möller
President
MDSS GmbH



MDSS - Schiffgraben 41 - 30175 Hannover, Germany

Hartalega NGC Sdn. Bhd.
Khairunnisa Warsito
No. 1, Persiaran Tanjung
Kawasan Perindustrian Tanjung
43900 Sepang, Selangor
MALAYSIA

Schiffgraben 41
30175 Hannover, Germany

Tel: + 49 - 511 - 62 62 86 30
Fax: + 49 - 511 - 62 62 86 33

eMail: info@mdss.com
Internet: www.mdss.com

2019.01.18

Confirmation of CE Registration

Dear Khairunnisa,

It is our pleasure to enclose the new Certificate of CE-Registration for your product.

Please note that registration was performed under § 25 MPG (Medizinproduktegesetz). This is the *Federal Republic of Germany's national interpretation of Medical Device Directive 93/42/EEC*. Registration is therefore in accordance with EU legislation. We remind you that all products must meet the applicable provision of the European and national regulation before they may be placed on the market.

We are looking forward to continuing our good business relationship and wish you a successful product launch in Europe.

Best regards,

Juan Monferrer Tena
Administrative Assistant
Medical Device Safety Service GmbH

Encl.
1 Certificate of CE-Registration
1 Annex A

MDSS - Medical Device Safety Service GmbH
Handelsregister Hannover HRB 57318 - USt-IdNr. DE 177346163 - Geschäftsführer: Ludger Möller

Bankverbindungen
Sparkasse Hannover
S.W.I.F.T.: SPHHD22H
IBAN: DE24 2505 0180 0910 0792 77

Commerzbank AG, Hannover
S.W.I.F.T.: COBADE33
IBAN: DE67 2504 0066 0338 8816 00



01.18.19 - 2019.01.18

Annex A dated January 18, 2019
Manufacturer: Hartalega NGC Sdn. Bhd.

UMDINS Code Description Notified Medical Device Product Name & Catalogue Number	UMDINS Code	Risk Class	Cat. Code	Registration Number	NB No. / NB Certificate No.	NB Cert. Valid Until YYYY-MM-DD
Gloves, Examination/Treatment Latex Examination Gloves; Nitrile Examination Gloves; Antimicrobial Nitrile Power Free Examination Gloves	11-882	1	10	DE/CA09/0170/H13/001-01	N.A.	N.A.
Latex Powder Free Examination Gloves						
Latex Powdered Examination Gloves						
Nitrile Powder Free Examination Gloves						
Antimicrobial Nitrile Power Free Examination Gloves						



FDA Home³ Medical Devices⁴ Databases⁵

510(K) Premarket Notification
1 to 10 of 82 Results
for Hartalega

1 2⁶ 3⁷ 4⁸ 5⁹ 6¹⁰ 7¹¹ 8¹² 9¹³ >¹⁴

10 results per page

New Search¹⁵ Export To Excel |
 Help¹⁶

Device Name ▲17 ▼18	Applicant ▲19 ▼20	510(K) Number ▲21 ▼22	Decision Date ▲23 ▼24
Powdered Sterile Latex Surgical Glove, With Protein Content Labeling Claim (200 Micrograms Or Less)	HARTALEGA SDN BHD	K001959	07/26/2000
Powder Free Sterile Latex Surgical Gloves, Contains 50 Microgram Or Less Of Total Water Extractable Protein Per Gram	HARTALEGA SDN BHD	K002593	11/29/2000
Freeform Blue Powderfree Nitrile Examination Gloves	HARTALEGA SDN BHD	K022671	11/18/2002
Freeform Blue Powder-free Nitrile Examination Gloves	HARTALEGA SDN BHD	K041391	07/09/2004
Nitrile Powder Free Examination Gloves (White)	HARTALEGA SDN BHD	K050214	03/16/2005
Nitrile Powdered Examination Gloves (White)	HARTALEGA SDN BHD	K050215	03/11/2005
Chlorinated Powder Free Latex Examination Gloves (Yellow)	HARTALEGA SDN BHD	K050277	06/07/2005
Nitrile Powder Free Examination Gloves (Blue)	HARTALEGA SDN BHD	K051777	08/12/2005

FDA LIVE LINK

https://www.accessdata.fda.gov/cdrh_docs/pdf18/K180505.PDF

<https://fda.report/Company/HARTALEGA+SDN+BHD>

510(k) Premarket Notification

[FDA Home](#) [Medical Devices](#) [Databases](#)



[510\(k\)](#) | [DeNovo](#) | [Registration & Listing](#) | [Adverse Events](#) | [Recalls](#) | [PMA](#) | [HDE](#) | [Classification](#) | [Standards](#)
[CFR Title 21](#) | [Radiation-Emitting Products](#) | [X-Ray Assembler](#) | [Medsun Reports](#) | [CLIA](#) | [TPLC](#)

[New Search](#)

[Back To Search Results](#)

Device Classification Name	Polymer Patient Examination Glove
510(K) Number	K133956
Device Name	NITRILE POWDER FREE EXAMINATION GLOVE WITH COLLOIDAL OATMEAL USP SKIN PROTECTANT DRUG - WHITE / DAWN BLUE / LEMON GREEN
Applicant	HARTALEGA SDN BHD NO. 7, KAWASAN PERUSAHAAN SURIA Bestari Jaya, Selangor, MY 45600
Applicant Contact	Nurul Aisyah Kong
Correspondent	HARTALEGA SDN BHD NO. 7, KAWASAN PERUSAHAAN SURIA Bestari Jaya, Selangor, MY 45600
Correspondent Contact	Nurul Aisyah Kong
Regulation Number	880.6250
Classification Product Code	LZA
Date Received	12/23/2013
Decision Date	05/28/2014
Decision	Substantially Equivalent (SESE)
Regulation Medical Specialty	General Hospital
510k Review Panel	General Hospital
Summary	Summary
Type	Traditional
Reviewed By Third Party	No
Combination Product	No



Trade/Device Name: Nitrile Powder Free Examination Glove with Colloidal Oatmeal USP with Low-Dermatitis Potential Claim and Tested For Use with Chemotherapy Drugs (White)

Regulation Number: 21 CFR 880.6250
Regulation Name: Patient Examination Glove
Regulatory Class: Class I
Product Code: LZA, LZC
Dated: May 15, 2018
Received: May 17, 2018

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the [Federal Register](#).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good

manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/>) and CDRH Learn (<http://www.fda.gov/Training/CDRHLearn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<http://www.fda.gov/DICE>) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Clarence W. Murray

iii III -S

For Tina Kiang, Ph.D.

Acting Director

Division of Anesthesiology,

General Hospital, Respiratory,

Infection Control, and Dental Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

Indications for Use

See PRA Statement below.

Device Name

Nitrile Powder Free Examination Glove with Colloidal Oatmeal USP with Low Dermatitis Potential Claim and Tested for Use with Chemotherapy Drugs (White)

Indications for Use (Describe)

Nitrile Powder Free Examination Glove with Colloidal Oatmeal USP with Low Dermatitis Potential Claim and Tested for Use with Chemotherapy Drugs (White) is a non-sterile disposable device intended for medical purpose that is worn on the examiner's hand to prevent contamination between patient and examiner. Is it also tested to be used against Chemotherapy Drugs.

The list of Chemotherapy Drugs tested (with breakthrough times) is as below:

Carmustine (3.3 mg/ml)	17.2 minutes
Cisplatin (1.0 mg/ml)	> 240 minutes
Cyclophosphamide (20 mg/ml)	> 240 minutes
Dacarbazine (10.0 mg/ml)	> 240 minutes
Doxorubicin Hydrochloride (2.0 mg/ml)	> 240 minutes
Etoposide (20 mg/ml)	> 240 minutes
Fluorouracil (50 mg/ml)	> 240 minutes
Methotrexate (25 mg/ml)	> 240 minutes
Mitomycin C (0.5 mg/ml)	> 240 minutes
Paclitaxel (6.0 mg/ml)	> 240 minutes
Thiotepa (10.0 mg/ml)	36.1 minutes
Vincristine Sulfate (1.0 mg/ml)	> 240 minutes

Do not use with Carmustine. Do not use with Thiotepa.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

"DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW."

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRASTaff@fda.hhs.gov

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number.

Testing. Development. Problem Solving.



April 15, 2009

• **TEST REPORT** •

PN 83672A - Amended


CHEMICAL ANALYTICAL SERVICES

Prepared For:
Hartalega SDN. BDH
Ms. Nurul Aisyah Kong
No. 7 Kawasan Perusahaan Suria
Bestari Jaya
Selangor, 45600
Malaysia

Prepared By:


Tiffany L. Heller
Chemical Technician

Approved By:


Ana C. Barbur, M.S.
Manager, Chemical & Pharmaceutical Services

An A2LA Accredited Testing Laboratory — Certificate Numbers 255.01 & 255.02
ISO 9001:2000 Registered
Member of ACIL: The American Council of Independent Laboratories



ISO 9001:2000
Registered



Letters and reports are for the exclusive use of the clients to whom they are addressed and shall not be reproduced, except in full, without the written permission of Akron Rubber Development Laboratory, Inc. (ARDL). The information contained herein applies to the specific material, products or processes tested or evaluated. No warranty of any kind is herein construed or implied. The liability of ARDL, Inc. shall be limited to the amount of consideration paid for services. ARDL, Inc. is accredited by A2LA for the test methods listed on the attached scope.

www.ardl.com

2887 Gilchrist Rd. | Akron, Ohio 44305 | answers@ardl.com
Toll Free (800) 830-ARDL | Worldwide (330) 794-6600 | Fax (330) 794-6610

Testing, Development, Problem Solving.

April 15, 2009

Ms. Nurul Aisyah Kong
Hartalega SDN. BHD

Page 1 of 3 – PN 83672A - Amended

SUBJECT: Permeation testing per ASTM D 6978-05 on sample submitted by the above company. Wire Transfer.

RECEIVED: Glove sample identified as Nitrile Powder Free Examination Gloves (Blue) Code: ABLU.

TESTING CHEMOTHERAPY DRUGS:

Table 1. List of the Testing Chemotherapy Drugs, Sources, and Expiration Dates

TESTING CHEMOTHERAPY DRUGS	DRUG SOURCE
Carmustine (BCNU)	Sigma; Lot# 038K4008; Expiration 12/2009
Cisplatin	Sigma; Lot# 59H3657; Expiration 09/2009
Cyclophosphamide (Cytoxan)	Sigma; Lot# 068K1131; Expiration 1/2010
Dacarbazine (DTIC)	Hospira; Lot# U022223AA; Expiration 06/2010
Doxorubicin Hydrochloride	Teva; Lot#07N625; Expiration 10/2009
Etoposide (Toposar)	Teva; Lot# 31303976B; Expiration 9/2011
Fluorouracil	APP; Lot# 203867; Expiration 03/2010
Mitomycin C	Sigma; Lot# 048K1086; Expiration 01/2010
Methotrexate	Hospira; Lot# U024457AA; Expiration 05/2010
Paclitaxel (Taxol)	Dabur Oncology; Lot# PA08H00701; Exp. 05/2010
Thiotepa	Sigma; Lot#078K1526; Expiration 12/2009
Vincristine Sulfate	Hospira; Lot# U037139AA; Expiration 12/2009

COLLECTION MEDIA:

The collection media, which were selected, are listed in Table 2.

Table 2. Collection Media for Testing Chemotherapy Drugs

TEST DRUG AND CONCENTRATION	COLLECTION MEDIUM
Carmustine (BCNU), 3.3 mg/ml (3,300 ppm)	10% Ethanol Aqueous Solution
Cisplatin, 1.0 mg/ml (1,000 ppm)	Distilled Water
Cyclophosphamide (Cytoxan), 20 mg/ml (20,000 ppm)	Distilled Water
Dacarbazine (DTIC), 10.0 mg/ml (10,000 ppm)	Distilled Water
Doxorubicin Hydrochloride, 2.0 mg/ml (2,000 ppm)	Distilled Water
Etoposide (Toposar), 20.0 mg/ml (20,000 ppm)	Distilled Water
Fluorouracil, 50.0 mg/ml (50,000 ppm)	9.20 pH Sodium Hydroxide Solution
Methotrexate, 25 mg/ml (25,000 ppm)	Distilled Water
Mitomycin C, 0.5 mg/ml (500 ppm)	Distilled Water
Paclitaxel (Taxol), 6.0 mg/ml (6,000 ppm)	30% Methanol Aqueous Solution
Thiotepa, 10.0 mg/ml (10,000 ppm)	Distilled Water
Vincristine Sulfate, 1.0 mg/ml (1,000 ppm)	Distilled Water

EC Declaration of Conformity

We, the manufacturer

Hartalega NGC Sdn. Bhd.,
No. 1, Persiaran Tanjung,
Kawasan Perindustrian Tanjung,
43900 Sepang,
Selangor Darul Ehsan,
Malaysia

with European Representative

Medical Device Safety Service (MDSS)
Schiffgraben 41, 30175 Hannover,
Germany

Declares that the new PPE described hereafter

Category III (Type C)
HNGC-TF-PPE-002
Antimicrobial Nitrile Powder Free Examination Gloves
Five fingered, chlorinated, powder free nitrile gloves, with textured fingers and beaded cuff. Thickness ≥ 2.2 mil

is in conformity with the relevant Union harmonisation legislation

PPE Regulation (EU) 2016/425


where such is the case, with the national standard transposing harmonized standard number

EN 420: 2003+A1: 2009
EN ISO 374 - 1:2016
EN ISO 374 - 5:2016

The notified body SATRA Technology Centre with Notified Body Number of 2777 performed the EU type-examination (Module B) and issued the EU type-examination certificate 2777/11723-01/E00-00.

the PPE is subject to the conformity assessment procedure conformity to type based on internal production control plus supervised product checks at random intervals (Module C2) under surveillance of the Notified body SATRA Technology Centre with Notified Body Number of 2777.

Done at Hartalega NGC Sdn. Bhd. on 11th February 2020.



Kuan Eu Jin
Quality Management Representative

Report No. : CRSSA/02646/18

TEST REPORT

Product Description : Powder Free Nitrile Examination Gloves
 Country of Origin : Malaysia
 Size : Medium
 Quantity Tested : 13 pieces
 Test Conducted : Dimensions
 Test Method : EN 455 Part 2:2015
 Testing Period : 02 Mar 2018 – 08 Mar 2018

Based on submitted samples, the following results obtained :-

Size	M	M	M	M	M	M	M	M	M	M	M	M	M	Median
Width	98	98	96	98	98	97	98	97	98	97	96	97	97	97
Length	250	255	250	255	251	250	252	252	250	254	252	253	252	252

Note: Upon Customer's request, this report has been issued in more than one original. Only the first original is a legally binding document and may be used for any legal purpose, including payment. (Original 1-3)

SGS (MALAYSIA) SDN. BHD.



CHEE TUCK CHOON
 B.Sc. MMIC
 SECTION HEAD

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Document.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested and such sample(s) are retained for seven days (perishable food sample) or three months only.

SGS (Malaysia) Sdn. Bhd. | Lot 4, Persiaran Jubli Perak, Seksyen 22, 40300 Shah Alam, Selangor, Malaysia
 (Company No. 10871-T) | t +6 (03) 5481 8282 f +6 (03) 5481 8215 www.sgs.com

QGWS.MH49134 - Protective Clothing and Ensembles for Emergency Medical Operations

Protective Clothing and Ensembles for Emergency Medical Operations

See General Information for Protective Clothing and Ensembles for Emergency Medical Operations

HARTALEGA SDN BHD

MH49134

C-G-9 Jalan Dataran Sd1

Dataran Sd Pju 9

Bandar Sri Damansara

52200 Kuala Lumpur, MALAYSIA

Protective clothing, equipment and [C]BRN ensembles for emergency medical operations in accordance with NFPA 1999 (2018)

Single-use emergency medical examination gloves

Type	Model/Style	UL Certification No.
Nitrile	Glove On Maverick LC	49134010301
Nitrile	HSB 41 (Orange) or GloveOn Vigor	49134010302
Nitrile	HSB 45 (Black)	49134010303
Nitrile	HSB 78 (Orange) or GloveOn Vigor LC	49134010304
Nitrile	HSB 78 (Black) or GloveOn Hammer LC	49134010305
Nitrile	HSB 71	49134010306

Last Updated on 2019-12-23

The appearance of a company's name or product in this database does not in itself assure that products so identified have been manufactured under UL's Follow-Up Service. Only those products bearing the UL Mark should be considered to be Certified and covered under UL's Follow-Up Service. Always look for the Mark on the product.

UL permits the reproduction of the material contained in the Online Certification Directory subject to the following conditions: 1. The Guide Information, Assemblies, Constructions, Designs, Systems, and/or Certifications (files) must be presented in their entirety and in a non-misleading manner, without any manipulation of the data (or drawings). 2. The statement "Reprinted from the Online Certifications Directory with permission from UL" must appear adjacent to the extracted material. In addition, the reprinted material must include a copyright notice in the following format: "© 2020 UL LLC"